secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001193125-23-071465
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organovo acquires Metacrine's FXR program for $4M cash
------------------------------------------------------

- Total cash consideration of $4M; $2M paid at closing and $2M due after transfer of program.
- Acquired FXR program from Metacrine, targeting NASH and liver diseases.
- Purchase Agreement entered into and closed on March 10, 2023.
- Customary representations, warranties, and closing conditions included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000119312523071465/0001193125-23-071465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000119312523071465/d401508d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-071465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer